Latest / Cyrus Webb's tracks / Dr. Dale Umetsu discusses Beyond Avoidance on Conversations LIVE

Transcript

Dr. Dale Umetsu discusses Beyond Avoidance on Conversations LIVE · Cyrus Webb's tracks

• 0:00
  Speaker 1: Hello, everyone, and welcome back to Conversations Live.
• 0:02
  Speaker 2: I'm your host, Cyrus Webb.
• 0:03
  Speaker 1: Glad you all could join us once again.
• 0:05
  Speaker 2: For our radio audience.
• 0:06
  Speaker 1: Tuning in in Mississippi at WYED 94.1 FM and WYEDonline.com,
• 0:11
  Speaker 1: we're glad that you all can be with us. Also,
• 0:13
  Speaker 1: join us online worldwide via our podcast at iHeartRadio and
• 0:16
  Speaker 1: Amazon Music, as well as through Conversations Radio Network. We're
• 0:19
  Speaker 1: glad you all could be with us as well.
• 0:21
  Speaker 2: We're excited to welcome Dr.
• 0:23
  Speaker 1: Dale DiUmezzo to our broadcast today. He's the author of
• 0:26
  Speaker 1: a new book called Beyond Avoidance, A Physician's Pursuit, to
• 0:30
  Speaker 1: transform food allergy therapy.
• 0:31
  Speaker 2: I want to talk to Dr.
• 0:33
  Speaker 1: Ometu not only about his own work, but also what
• 0:36
  Speaker 1: it's been like for him to see the advancements that
• 0:38
  Speaker 1: have been made, how we better understand food allergies, but
• 0:41
  Speaker 1: also how they definitely have transformed the way we think
• 0:45
  Speaker 1: about them in the past, and also, of course, about
• 0:47
  Speaker 1: the future of those who deal with food allergies today.
• 0:50
  Speaker 1: If you guys are just now finding out about the book,
• 0:52
  Speaker 1: Beyond Avoidance, we'll let you know how you can get
• 0:54
  Speaker 1: your own copy of it.
• 0:56
  Speaker 2: But, Dr. Ometu, thank you again for stopping by. I
• 0:58
  Speaker 2: really appreciate it.
• 0:59
  Speaker 3: My pleasure. Thanks for having me.
• 1:01
  Speaker 2: The pleasure is.
• 1:02
  Speaker 1: Definitely all mine. This is an important topic, I think,
• 1:04
  Speaker 1: for our audience, but what I really have to be
• 1:07
  Speaker 1: honest with you and say, the human interest side of it,
• 1:10
  Speaker 1: your story, is one that is also fascinating.
• 1:12
  Speaker 2: I want to begin there.
• 1:14
  Speaker 1: What was it like for you not only to be
• 1:16
  Speaker 1: able to write about something you devoted so much time to,
• 1:19
  Speaker 1: that being food allergies, but also your own personal journey
• 1:22
  Speaker 1: in the work?
• 1:24
  Speaker 3: It was certainly a journey because You know, I've been
• 1:29
  Speaker 3: in academic medicine for 30 years and to transition into
• 1:35
  Speaker 3: drug development, joining Genentech was a real transition. It was
• 1:41
  Speaker 3: somewhat of a crazy idea. It was risky on my
• 1:44
  Speaker 3: part because I knew very little about the pharmaceutical industry.
• 1:50
  Speaker 3: So it was a risky journey and I wanted to
• 1:55
  Speaker 3: tell people about that.
• 1:56
  Speaker 1: Yeah. You know, I think, you know, even in the
• 2:00
  Speaker 1: title of the book, Beyond Avoidance, I think it says
• 2:03
  Speaker 1: so much not only about the topic of food allergies,
• 2:06
  Speaker 1: but also I think when it comes to advancement as well.
• 2:09
  Speaker 1: I want to talk about the food allergy aspect because
• 2:12
  Speaker 1: I have talked to people over the years, Dr. Matthew,
• 2:15
  Speaker 1: on this broadcast who have been impacted by food allergies and,
• 2:19
  Speaker 1: of course, have family members have as well.
• 2:22
  Speaker 2: What does it feel like for you to see the way.
• 2:24
  Speaker 1: That that not only the way that we are able
• 2:27
  Speaker 1: to treat individuals who deal with food allergies has evolved,
• 2:31
  Speaker 1: but also our understanding of those food allergies as well.
• 2:34
  Speaker 3: Well, clearly, over my career of 30, 40 years, initially,
• 2:41
  Speaker 3: food allergy wasn't a big issue. But over the last 20,
• 2:45
  Speaker 3: 30 years, it's become much, much more prevalent. And in addition,
• 2:51
  Speaker 3: what I've clearly understood over time was that there was
• 2:55
  Speaker 3: very little we could do to offer patients except to
• 2:58
  Speaker 3: have them avoid the food and then to treat accidental exposures,
• 3:06
  Speaker 3: those reactions that occur with accidental exposures. So now with
• 3:11
  Speaker 3: Zolair approved, we have a very effective treatment for food allergy.
• 3:17
  Speaker 3: So it makes going out into the community for these
• 3:22
  Speaker 3: patients much less risky. And because we have a treatment,
• 3:28
  Speaker 3: it can cause much less anxiety.
• 3:31
  Speaker 1: In the book, and I love the way you break
• 3:33
  Speaker 1: it down because, again, it does get into the personal
• 3:37
  Speaker 1: as well as the professional aspect of what we're talking
• 3:41
  Speaker 1: about here in Chapter 5, Milk and Courage.
• 3:45
  Speaker 2: That is one of those big.
• 3:46
  Speaker 1: Chapters where you, of course, before that chapter, you talked
• 3:50
  Speaker 1: about the trials. I want to talk about that because
• 3:53
  Speaker 1: I think A lot of times we don't realize, and
• 3:55
  Speaker 1: we may hear Dr. Umetsu, and I've talked about it
• 3:59
  Speaker 1: on this program, about these clinical trials that take place.
• 4:02
  Speaker 1: I don't think people always realize the importance of those.
• 4:05
  Speaker 1: What does it feel like for you to see the
• 4:07
  Speaker 1: impact those have had on the advancements being made today?
• 4:11
  Speaker 3: So personally, I was involved with that first trial with
• 4:16
  Speaker 3: Solaire and oral immunotherapy for milk. And, you know, when we...
• 4:24
  Speaker 3: we're doing the trial, we weren't fully sure that it
• 4:28
  Speaker 3: would work. And so having the patient take Xolair and
• 4:37
  Speaker 3: then tolerate large amounts of the milk was just amazing
• 4:44
  Speaker 3: to me. And that's what convinced me that Xolair was
• 4:48
  Speaker 3: an incredible product in that it should be available to patients.
• 4:53
  Speaker 3: And so that's why I thought that we needed to
• 4:58
  Speaker 3: convince Genentech that it needed to be FDA-approved.
• 5:04
  Speaker 2: You know, part of this story, I think, Dr.
• 5:07
  Speaker 1: Umezu, that is so important, and I hope our audience
• 5:10
  Speaker 1: is open enough to this. You know, there's been so
• 5:13
  Speaker 1: much that's been said about the pharmaceutical industry, and I
• 5:18
  Speaker 1: think one thing that this book really does help us
• 5:20
  Speaker 1: understand is that You know, it's not always the way
• 5:25
  Speaker 1: it has been categorized, that the pharmaceutical industry, that these
• 5:29
  Speaker 1: clinical trials, this testing, this funding, is all going toward
• 5:33
  Speaker 1: being able to help provide solutions.
• 5:36
  Speaker 2: Has part of.
• 5:37
  Speaker 1: The conversation been for you with people in better helping
• 5:41
  Speaker 1: them understand not only the importance of these trials, but
• 5:46
  Speaker 1: also of the impact of things like that are being
• 5:50
  Speaker 1: done with the advancements?
• 5:52
  Speaker 3: Well, I think the book helps to point out a
• 5:57
  Speaker 3: lot of the hurdles that we need to go through
• 6:02
  Speaker 3: and companies need to go through in order to get
• 6:06
  Speaker 3: a medication approved. So, for example, with Zolair, it's a biologic,
• 6:13
  Speaker 3: meaning that it's a relatively expensive medication. And initially, many
• 6:19
  Speaker 3: people thought that food allergy was not a serious disease
• 6:24
  Speaker 3: enough to warrant using a biologic, even though biologics are
• 6:30
  Speaker 3: used a lot for treatments of more serious diseases, say cancer.
• 6:36
  Speaker 3: And another issue that came up was that solar was
• 6:41
  Speaker 3: an old product when we started looking at it for
• 6:44
  Speaker 3: food allergy. Its patents were expiring. So at Genentech, They
• 6:51
  Speaker 3: were more interested in the newer drugs that were used
• 6:55
  Speaker 3: for other treatments to, and so they wanted to invest
• 6:59
  Speaker 3: in those newer drugs rather than an old drug that
• 7:02
  Speaker 3: had patents that were expiring. And another hurdle that we
• 7:07
  Speaker 3: had to deal with was that the FDA had significant reservations.
• 7:14
  Speaker 3: They were not really sure how to deal with that
• 7:16
  Speaker 3: biologic or food allergy. and what criteria to use to
• 7:21
  Speaker 3: assess how effective it might be for food allergy. So
• 7:26
  Speaker 3: all of these issues were fairly significant and prevented a
• 7:31
  Speaker 3: lot of interest in pursuing Xolair as a new treatment
• 7:35
  Speaker 3: for food allergy.
• 7:39
  Speaker 1: And again, that is why I think hearing it from you,
• 7:43
  Speaker 1: as someone who was literally on the front lines, I
• 7:45
  Speaker 1: think makes this something that's so much more impactful. but
• 7:49
  Speaker 1: also that people will really be able to benefit from.
• 7:52
  Speaker 1: Is this something that you knew would be inevitable for you, Dr. Matu,
• 7:56
  Speaker 1: that you would write a book?
• 8:01
  Speaker 3: Not at all, not at all. You know, I've spent
• 8:07
  Speaker 3: most of my time in academic medicine. I did write
• 8:10
  Speaker 3: a lot of academic papers for journals. I had to
• 8:13
  Speaker 3: write a lot of grant applications, but I really never thought,
• 8:17
  Speaker 3: of writing a book about what I had gone through.
• 8:24
  Speaker 2: So I was saying.
• 8:25
  Speaker 1: To you before we went on the air here, one
• 8:27
  Speaker 1: of the things that I was curious about was the timing.
• 8:30
  Speaker 1: Why did you decide now was the time?
• 8:32
  Speaker 3: Sure. Well, you know, it took a long time to
• 8:37
  Speaker 3: get Zolaire approved. I joined Genentech in 2013, and the
• 8:42
  Speaker 3: FDA approved Zolaire in 2013. 2024. It took a long time.
• 8:52
  Speaker 3: And so I thought that since it was approved two
• 8:57
  Speaker 3: years ago that it might be a good time to
• 9:00
  Speaker 3: let people know the difficulties that we encountered in getting
• 9:07
  Speaker 3: Zolair approved for food allergy. So I thought this might
• 9:11
  Speaker 3: be a good time.
• 9:13
  Speaker 1: And now here we are again having this book. And
• 9:16
  Speaker 1: I think something that people can be able to read
• 9:20
  Speaker 1: and be able to understand. I think that's one of
• 9:22
  Speaker 1: the things I want to say for our audience is
• 9:24
  Speaker 1: the book is written in a way that anyone can
• 9:27
  Speaker 1: be able to pick it up and really, I think,
• 9:28
  Speaker 1: be able to glean not only the importance of this work,
• 9:32
  Speaker 1: but also, of course, what has led up to it
• 9:35
  Speaker 1: for sure. I want to say for those who are
• 9:37
  Speaker 1: just tuning in, welcome.
• 9:38
  Speaker 2: You all are.
• 9:39
  Speaker 1: Listening to Conversations Live. We're excited to welcome Dr. Dale
• 9:42
  Speaker 1: Tiametsu to our broadcast today. He's the author of the
• 9:45
  Speaker 1: new book, Beyond Avoidance, A Physician's Pursuit to Transform Food
• 9:50
  Speaker 1: Allergy Therapy. We're going to also let you all know
• 9:53
  Speaker 1: how to stay connected with Dr. Emetsu as well as
• 9:55
  Speaker 1: get your own copy of the book. At the time
• 9:57
  Speaker 1: we're having this conversation, Dr. Emetsu, you've have seen this already.
• 10:01
  Speaker 1: Your book is already an Amazon bestseller, which is exciting
• 10:06
  Speaker 1: in the category of bestsellers for children and adolescents' allergies.
• 10:11
  Speaker 1: The book is already ranking there. And I think, you know,
• 10:14
  Speaker 1: for a lot of people, that brings up this topic
• 10:16
  Speaker 1: because when we think about food allergies, a lot of
• 10:19
  Speaker 1: times We think about adults, but children, of course, are
• 10:23
  Speaker 1: definitely impacted by that, especially because of going to school
• 10:26
  Speaker 1: and being offered different things.
• 10:31
  Speaker 2: What has it been like.
• 10:31
  Speaker 1: For you to be a part of the educational aspect
• 10:34
  Speaker 1: of who food allergies do impact and the importance of
• 10:37
  Speaker 1: having things like this therapy available for all ages?
• 10:41
  Speaker 3: Well, it's been a privilege to treat patients one-on-one when
• 10:48
  Speaker 3: I see them in the clinic. But getting a medication
• 10:53
  Speaker 3: approved through the FDA, now we can help thousands of patients.
• 10:58
  Speaker 3: So I'm really just amazed and grateful that I've been
• 11:02
  Speaker 3: able to participate in such an endeavor to help patients
• 11:07
  Speaker 3: at a much larger level now with FDA approval of Zolair.
• 11:12
  Speaker 1: And you even allude to this even in the introduction
• 11:16
  Speaker 1: of the book talking about this for patients. you know,
• 11:19
  Speaker 1: parents packing backpacks, you know, with the epidurum pen. You know,
• 11:24
  Speaker 1: it's one of those things that's almost become, you know,
• 11:27
  Speaker 1: just commonplace for so many. And I think, you know,
• 11:31
  Speaker 1: so the idea of being able to have something that
• 11:33
  Speaker 1: really does provide them help, but a treatment option that
• 11:39
  Speaker 1: is something that they can benefit from is so important.
• 11:42
  Speaker 1: Who did you have in mind when you were writing Beyond.
• 11:44
  Speaker 2: Avoidance, Dr. Metz?
• 11:46
  Speaker 1: Because I For me, I mean, as someone who likes
• 11:49
  Speaker 1: to read about people's lives, I enjoyed, you know, the
• 11:53
  Speaker 1: journey of learning about you.
• 11:55
  Speaker 2: And your work.
• 11:56
  Speaker 1: But also, of course, I'm sure for people, you know,
• 11:58
  Speaker 1: who are impacted by food allergies, they will definitely be
• 12:01
  Speaker 1: interested in the more the medical side. But who did
• 12:04
  Speaker 1: you have in mind when you were writing the book?
• 12:06
  Speaker 3: Well, I know that food allergy is a very prevalent problem,
• 12:11
  Speaker 3: and I've taken care of a lot of these patients.
• 12:14
  Speaker 3: So I did have in mind my patients and other
• 12:17
  Speaker 3: patients with food allergy. I did think that they would
• 12:21
  Speaker 3: be very interested in hearing about how this drug Zolair
• 12:25
  Speaker 3: got approved for their use. But I also thought that
• 12:29
  Speaker 3: other people who are interested in simply the medical scenario,
• 12:36
  Speaker 3: how drugs get approved, I thought that this would be
• 12:39
  Speaker 3: very interesting. For me, I learned so much about the
• 12:44
  Speaker 3: FDA and drug approval after joining Genentech. So I was amazed,
• 12:49
  Speaker 3: and I thought other people would be amazed to hear
• 12:51
  Speaker 3: about that as well.
• 12:54
  Speaker 1: You say in the book about yourself, the quote that
• 12:58
  Speaker 1: I made a note of is, at every stop of
• 13:00
  Speaker 1: my journey, I wanted to leave things better than they
• 13:03
  Speaker 1: were when I arrived. And you've been able to really
• 13:06
  Speaker 1: do that, Dr. Matsu, when it comes to the advancements
• 13:10
  Speaker 1: in the course, helping when it comes to food allergies.
• 13:14
  Speaker 1: How does that feel to know that you've achieved that?
• 13:16
  Speaker 3: Yeah, well, you know, all along the way, my goal
• 13:20
  Speaker 3: has been simply to do my job, get things done,
• 13:25
  Speaker 3: and try to help people along the way and make
• 13:29
  Speaker 3: things better. And so it's been very gratifying to see
• 13:32
  Speaker 3: that I have been able to achieve at least some
• 13:35
  Speaker 3: of that. And so, yeah, I am very gratified that
• 13:40
  Speaker 3: I was able to participate in some of these endeavors
• 13:43
  Speaker 3: and to get things a little bit better for people.
• 13:49
  Speaker 1: You also show the human side of medicine, too, and
• 13:54
  Speaker 1: treating patients. And I think, again, we as individuals, we
• 13:59
  Speaker 1: don't always, even though we know, of course, physicians are human,
• 14:03
  Speaker 1: we don't always think about what they're feeling, right, when
• 14:07
  Speaker 1: we're going to see them You write in the book
• 14:10
  Speaker 1: when it comes to before you have the therapy available
• 14:15
  Speaker 1: that you do now, you say in the book this sentence,
• 14:19
  Speaker 1: and I want to be able to read it for
• 14:20
  Speaker 1: our audience. You said, it was becoming my reality as
• 14:23
  Speaker 1: a physician. I entered medicine to help people not to
• 14:26
  Speaker 1: watch powerlessly while they lived in a constant state of
• 14:30
  Speaker 1: worry and suffering. Why was that so important for you
• 14:33
  Speaker 1: to make sure people understood that, yes, that's your experience,
• 14:37
  Speaker 1: but that a lot of doctors don't? That's why they
• 14:40
  Speaker 1: became a physician, to be able to help people and
• 14:42
  Speaker 1: to make sure that therapy, like what's available now, is
• 14:46
  Speaker 1: something they can be able to offer.
• 14:48
  Speaker 3: So I certainly went into medicine to try to help people.
• 14:54
  Speaker 3: One of the frustrating things about food allergy is that
• 14:59
  Speaker 3: we had so little to offer patients. And so that
• 15:02
  Speaker 3: was a big frustration, I'm sure for patients, but also
• 15:06
  Speaker 3: for me. And that's what globally to pursue trying to
• 15:11
  Speaker 3: get better treatments for my patients.
• 15:16
  Speaker 1: And now here we are in 2026, where, as you mentioned,
• 15:20
  Speaker 1: of course, you know, thanks to the advancements that have
• 15:22
  Speaker 1: been made, you know, there is actually help. You know,
• 15:27
  Speaker 1: what has that been like for you to see the impact?
• 15:30
  Speaker 1: Because I think, you know, for so many people who
• 15:32
  Speaker 1: felt like they didn't have options to now have these options,
• 15:36
  Speaker 1: what has it been like for you to see the
• 15:38
  Speaker 1: impact that that this therapy and the work that you've
• 15:41
  Speaker 1: done has now had on other people.
• 15:44
  Speaker 3: It is amazing and so gratifying to hear from some
• 15:49
  Speaker 3: of my patients and other patients who I've never treated,
• 15:52
  Speaker 3: but some of them come up to me and say
• 15:55
  Speaker 3: how they've been so wonderfully impacted by starting Zolair for
• 16:00
  Speaker 3: food allergy. And it's just amazing to hear those kinds
• 16:04
  Speaker 3: of stories. And so I'm again, so grateful that I've
• 16:08
  Speaker 3: been able to participate in this journey to get Zola
• 16:12
  Speaker 3: to these patients.
• 16:14
  Speaker 2: And I know that they're happy as well.
• 16:16
  Speaker 1: When people finish Beyond Avoidance, Dr.
• 16:19
  Speaker 2: Yomet, so what is your hope?
• 16:20
  Speaker 1: What do you want them to remember about the book
• 16:24
  Speaker 1: and about the journey to where we are today when
• 16:26
  Speaker 1: it comes to help for those dealing with food allergies?
• 16:29
  Speaker 3: Well, I guess one thing is to understand that it
• 16:33
  Speaker 3: was a long journey to get to where we are.
• 16:37
  Speaker 3: But also that because Zolair is approved now that many
• 16:44
  Speaker 3: other companies are entering into this field and that there
• 16:49
  Speaker 3: are a number of new medications that are being studied
• 16:52
  Speaker 3: now and will be studied in the future. So I
• 16:56
  Speaker 3: think that new medications for food allergy are likely to
• 17:00
  Speaker 3: be had in the next five to 10 years.
• 17:07
  Speaker 1: When it came to the actual title of the book,
• 17:11
  Speaker 1: Beyond Avoidance, I thought about what you shared about, you know,
• 17:15
  Speaker 1: what so many people were having to live with, right?
• 17:18
  Speaker 1: And that is to be able to, you know, try
• 17:21
  Speaker 1: to make decisions to say, you know, you can't do this,
• 17:25
  Speaker 1: you can't have this. And you say in the book this,
• 17:29
  Speaker 1: and again, I think.
• 17:30
  Speaker 2: It's such a powerful statement, Dr.
• 17:31
  Speaker 1: Matthew, you say, was avoidance really the best strategy we
• 17:35
  Speaker 1: could offer these families? And then you went on to
• 17:38
  Speaker 1: say this when it came to yourself and what you've done.
• 17:43
  Speaker 1: You said, I couldn't stand on the sidelines anymore. I
• 17:45
  Speaker 1: hadn't gone to medical school to hand out EpiPens and
• 17:49
  Speaker 1: shrug my shoulders. I entered the medical field to make
• 17:52
  Speaker 1: sick people feel better, solve problems, and discover better treatments.
• 17:57
  Speaker 1: And I think when people read Beyond Avoidance, Dr. Metz,
• 18:00
  Speaker 1: we're able to see you're able to achieve that. On
• 18:03
  Speaker 1: a personal level, how does that feel to know that
• 18:06
  Speaker 1: exactly why you got into the profession is what has
• 18:10
  Speaker 1: led you to where you are now?
• 18:12
  Speaker 3: Well, as I talked about, when I used to see
• 18:16
  Speaker 3: patients with food allergy and we had very little to offer,
• 18:21
  Speaker 3: that was so frustrating and that kept driving me to
• 18:26
  Speaker 3: study the science of food allergy, the science of allergy,
• 18:30
  Speaker 3: and to strive for getting better treatments for patients. And
• 18:35
  Speaker 3: so it's amazing to see that we have a good
• 18:40
  Speaker 3: treatment now for food allergy with Zolair. And I think
• 18:46
  Speaker 3: it's going to be amazing to watch as additional treatments
• 18:51
  Speaker 3: become available for our patients.
• 18:55
  Speaker 2: Yeah. Well, it's a great read.
• 18:57
  Speaker 1: And I want to say congratulations to you and thank you, Dr. Ametsu,
• 19:01
  Speaker 1: for the great work You've been able to deal with
• 19:03
  Speaker 1: the relief and, of course, I think the options you've
• 19:07
  Speaker 1: been able to give to people who really were in
• 19:09
  Speaker 1: need and they may have felt, as you talk about
• 19:12
  Speaker 1: in the book, defeated. You've now given them hope, and
• 19:15
  Speaker 1: I know they appreciate that. Again, everyone, Dr.
• 19:18
  Speaker 2: Dale T.
• 19:19
  Speaker 1: Emetsu has been our guest. The book is called Beyond Avoidance,
• 19:23
  Speaker 1: A Physician's Pursuit to Transform Food Allergy Therapy. The book
• 19:27
  Speaker 1: is available through our friends, On Amazon.com, you can get
• 19:30
  Speaker 1: it in paperback, hardcover, or the Kindle edition. I have
• 19:33
  Speaker 1: the Kindle edition here. Or, of course, through your favorite
• 19:36
  Speaker 1: local bookstores. As I mentioned, it's already an Amazon.com bestseller.
• 19:41
  Speaker 2: Dr. Umetsu, how can our audience stay connected with you?
• 19:44
  Speaker 3: We have a website for the book. It's called DaleUmetsu.com.
• 19:51
  Speaker 3: And I'm happy to hear from people on the website.
• 19:55
  Speaker 2: All right.
• 19:56
  Speaker 1: I want to make sure that we link that up
• 19:57
  Speaker 1: as well. Thank you again, Dr. Umetsu, for stopping by.
• 20:00
  Speaker 1: I really appreciate the time and looking forward to speaking
• 20:02
  Speaker 1: with you again. Right.
• 20:04
  Speaker 3: Thank you so much, Cyrus. It's been a pleasure to
• 20:07
  Speaker 3: speak with you.
• 20:08
  Speaker 2: Thank you. I appreciate that.
• 20:09
  Speaker 1: And we thank your audience for tuning in to another
• 20:12
  Speaker 1: great segment of Conversations Live. Until next time, I'm your host,
• 20:15
  Speaker 1: Cyrus Webster. As always, enjoy your day, enjoy your life,
• 20:18
  Speaker 1: enjoy your world. Thank you for being with us here
• 20:20
  Speaker 1: at Conversations Live. Let's go make today amazing.
• 20:23
  Speaker 2: Take care.